secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-280116
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences Q3 revenue $3.3M (-16% YoY); adjusted EBITDA loss $118K; hemp regulatory language enacted with 1-yr delay
--------------------------------------------------------------------------------

- Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.
- Gross margin 48.5% (Q3 2024: 46.0%; Q2 2025: 50.9%); adjusted EBITDA loss $118K vs $75K loss in Q3 2024.
- Cash balance $0.4M at quarter-end; launched +PlusCBD Ignite men's formula. Federal hemp language enacted with one-year delay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000119312525280116/0001193125-25-280116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000119312525280116/cvsi-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-280116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer